Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder

• Published in: The Annals of pharmacotherapy Vol. 46; no. 5; p. 642
• Main Authors: Taneja, Charu, Papakostas, George I, Jing, Yonghua, Baker, Ross A, Forbes, Robert A, Oster, Gerry
• Format: Journal Article
• Language: English
• Published: United States 01.05.2012
• Subjects: Antidepressive Agents - adverse effects; Antidepressive Agents - economics; Antidepressive Agents - therapeutic use; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Antipsychotic Agents - economics; Antipsychotic Agents - therapeutic use; Aripiprazole; Benzodiazepines - adverse effects; Benzodiazepines - economics; Benzodiazepines - therapeutic use; Cost-Benefit Analysis - economics; Cost-Benefit Analysis - statistics & numerical data; Decision Support Techniques; Depressive Disorder, Major - diagnosis; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - economics; Dibenzothiazepines - adverse effects; Dibenzothiazepines - economics; Dibenzothiazepines - therapeutic use; Drug Combinations; Drug Costs - statistics & numerical data; Drug Resistance; Fluoxetine - adverse effects; Fluoxetine - economics; Fluoxetine - therapeutic use; Health Care Costs - statistics & numerical data; Humans; Piperazines - adverse effects; Piperazines - economics; Piperazines - therapeutic use; Quetiapine Fumarate; Quinolones - adverse effects; Quinolones - economics; Quinolones - therapeutic use
• ISSN: 1542-6270
• DOI: 10.1345/aph.1Q326

While the clinical utility of atypical antipsychotics has been established in patients with major depressive disorder (MDD) who are refractory to antidepressant therapy, their cost-effectiveness is unknown. To examine the cost-effectiveness of aripiprazole, quetiapine, and olanzapine/fluoxetine in adults with MDD who are refractory to antidepressant therapy. Using techniques of decision analysis, we estimated expected outcomes and costs over 6 weeks in adults with MDD receiving (1) aripiprazole 2-20 mg/day and antidepressant therapy; (2) quetiapine 150 mg/day or 300 mg/day and antidepressant therapy; (3) the fixed-dose combination of olanzapine 6, 12, or 18 mg/day with fluoxetine 50 mg/day; or (4) antidepressant therapy alone. Cost-effectiveness was assessed in terms of the cost per additional responder at 6 weeks, defined as the ratio of the difference in the cost of MDD-related care over 6 weeks versus antidepressant therapy alone to the difference in the number of patients achieving clinical response by 6 weeks. We estimated the model using data from Phase 3 clinical trials of atypical antipsychotics along with other secondary data sources. With antidepressant therapy alone, the estimated clinical response rate at 6 weeks was 30%. Aripiprazole, quetiapine 150 mg/day, quetiapine 300 mg/day, and olanzapine/fluoxetine were estimated to increase clinical response at 6 weeks to 49%, 34%, 38%, and 45%, respectively. Costs of MDD-related care over 6 weeks were estimated to be $192 for antidepressant therapy, $847 for aripiprazole, $541 for quetiapine 150 mg/day, $672 for quetiapine 300 mg/day plus antidepressant therapy, and $791 for olanzapine/fluoxetine. Costs per additional responder (vs antidepressant therapy) over a 6-week period were estimated to be $3447 for aripiprazole, $8725 for quetiapine 150 mg/day, $6000 for quetiapine 300 mg/day, and $3993 for olanzapine/fluoxetine. Atypical antipsychotics substantially increase clinical response at 6 weeks. Cost per additional responder is lower for aripiprazole than for quetiapine or olanzapine/fluoxetine.